SBP-0069330 is under clinical development by Camino Pharma and currently in Phase I for Smoking Cessation. According to GlobalData, Phase I drugs for Smoking Cessation does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the SBP-0069330 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SBP-0069330 overview
SBP-0069330 is under development for the treatment of substance abuse including cocaine addiction, alcohol use disorder and nicotine addiction. It is administered by oral route. The drug candidate acts by targeting metabotropic glutamate receptor 2.
For a complete picture of SBP-0069330’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.